Pipeline

Overview

The drug pipeline of Priavoid is composed of 6 compounds in development with 5 CNS diseases:

Alzheimer’s disease
Amyotrophic lateral sclerosis
Tauopathies
Huntington’s disease
Parkinson’s disease

PRI-002

Our current focus is on Phase II clinical trial of PRI-002, a synthetic all-D-peptide for causal treatment of Alzheimer’s disease.

Thus, PRI-002 has three unique selling propositions (USPs):

New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Priavoid follows a completely new strategy for treatment of Alzheimer’s disease.

We have developed stable D-peptides that are able to overcome the blood-brain barrier, do not interfere with formation or clearance with normal non-toxic Abeta monomers, but specifically eliminate cytotoxic Abeta oligomers.

Partnering

Partnering is a key component of Priavoids strategy

Learn more